Jodas is a Global, specialty, innovation driven,
emerging, generic pharmaceutical company, that is asserting itself among the
world’s foremost pharmaceutical companies. We began our journey of growth in
the year 2006 in India, and today Jodas is a modern, research driven
organization that has quality and affordability at the heart of its activities.
Jodas focuses its operations on four
speciality therapeutic segments:
·
Anti
Infectives (Injectables & Orals)
·
Anti
Cancer (Injectables & Orals)
·
Contrast
Media – Injectables
·
Critical
Care (Injectables & Orals)
Our dedicated team of healthcare professionals strives to
bring specialty, high-quality, effective and affordable generic formulations to
the market, touching millions of lives with good health.
Jodas has 40+ approved products in targeted emerging markets
with State-of-the-art world-class manufacturing facilities and has successfully
commercialized 7 million Injectables in the year 2014, with unparalleled
customer satisfaction.
Focused to grow further in Emerging markets. The future
endeavor is to be a Global generic player in highly regulated markets. We are
committed to be “ONE STEP BETTER”, to fulfill the unmet medical needs of the
healthcare community around the Globe with branded generic formulations of
uncompromising quality.
Jodas has constantly upped the benchmark in uncompromising
quality, with a pulse on rapidly changing innovation to commercialization
landscape through our selection of a product range of affordable medicines and
speed-to-the-market, along with our partners and Global supply chain.
We continuously evolve our business focus with a
customer–centered portfolio of niche and technologically challenging products
from specialty and therapeutic segments.
Our continuous focus on innovation and quality drives us to
fulfill the unmet medical needs of the healthcare community and make the dreams
of millions of people across the world come true with much needed medicines at
an affordable value.
For more updates
follow
Thank you for visiting my website, Visit again
for
latest pharma updates
No comments:
Post a Comment